Skip to main content
Top
Published in: Tumor Biology 10/2016

01-10-2016 | Original Article

Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process

Authors: Paola R. Gonçalves, Karin J. P. Rocha-Brito, Maruska R. N. Fernandes, Julia L. Abrantes, Nelson Durán, Carmen V. Ferreira-Halder

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

Treatment of metastatic melanoma still remains a challenge, since in advanced stage it is refractory to conventional treatments. Most patients with melanoma have either B-RAF or N-RAS mutations, and these oncogenes lead to activation of the RAS-RAF-MEK-ERK and AKT signal pathway, keeping active the proliferation and survival pathways in the cell. Therefore, the identification of small molecules that block metastatic cell proliferation and induce cell death is needed. Violacein, a pigment produced by Chromobacterium violaceum found in Amazon River, has been used by our group as a biotool for scrutinizing signaling pathways associated with proliferation, survival, aggressiveness, and resistance of cancer cells. In the present study, we demonstrate that violacein diminished the viability of RAS- and RAF-mutated melanoma cells (IC50 value ∼500 nM), and more important, this effect was not abolished after treatment medium removal. Furthermore, violacein was able to reduce significantly the invasion capacity of metastatic melanoma cells in 3D culture. In the molecular context, we have shown for the first time that violacein causes a strong drop on histone deacetylase 6 expression, a proliferating activator, in melanoma cells. Besides, an inhibition of AXL and AKT was detected. All these molecular events propitiate an inhibition of autophagy, and consequently, melanoma cell death by apoptosis.
Literature
22.
go back to reference Mehta T, Vercruysse K, Johnson T, Ejiofor AO, Myles E, Quick QA. Violacein induces p44/42 mitogen-activated protein kinase-mediated solid tumor cell death and inhibits tumor cell migration. Mol Med Rep. 2015;12(1):1443–8. doi:10.3892/mmr.2015.3525.PubMedPubMedCentral Mehta T, Vercruysse K, Johnson T, Ejiofor AO, Myles E, Quick QA. Violacein induces p44/42 mitogen-activated protein kinase-mediated solid tumor cell death and inhibits tumor cell migration. Mol Med Rep. 2015;12(1):1443–8. doi:10.​3892/​mmr.​2015.​3525.PubMedPubMedCentral
23.
go back to reference Masuelli L, Pantanella F, La Regina G, Benvenuto M, Fantini M, Mattera R, et al. Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo. Tumour Biol. 2015;1–13. doi 10.1007/s13277-015-4207-3. Masuelli L, Pantanella F, La Regina G, Benvenuto M, Fantini M, Mattera R, et al. Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo. Tumour Biol. 2015;1–13. doi 10.​1007/​s13277-015-4207-3.
25.
go back to reference Rettori D, Duran N. Production, extraction and purification of violacein: an antibiotic pigment produced by Chromobacterium violaceum. World J Microbiol Biotechnol. 1998;14:685–8.CrossRef Rettori D, Duran N. Production, extraction and purification of violacein: an antibiotic pigment produced by Chromobacterium violaceum. World J Microbiol Biotechnol. 1998;14:685–8.CrossRef
27.
28.
go back to reference Alonso-Curbelo D, Riveiro-Falkenbach E, Pérez-Guijarro E, Cifdaloz M, Karras P, Osterloh L, Megías D, Cañón E, Calvo TG, Olmeda D, Gómez-López G, Graña O, Sánchez-Arévalo Lobo VJ, Pisano DG, Wang HW, Ortiz-Romero P, Tormo D, Hoek K, Rodríguez-Peralto JL, Joyce JA, Soengas MS. RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. Cancer Cell. 2014;26(1):61–76. doi:10.1016/j.ccr.2014.04.030.CrossRefPubMed Alonso-Curbelo D, Riveiro-Falkenbach E, Pérez-Guijarro E, Cifdaloz M, Karras P, Osterloh L, Megías D, Cañón E, Calvo TG, Olmeda D, Gómez-López G, Graña O, Sánchez-Arévalo Lobo VJ, Pisano DG, Wang HW, Ortiz-Romero P, Tormo D, Hoek K, Rodríguez-Peralto JL, Joyce JA, Soengas MS. RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. Cancer Cell. 2014;26(1):61–76. doi:10.​1016/​j.​ccr.​2014.​04.​030.CrossRefPubMed
31.
go back to reference de Fátima A, Zambuzzi WF, Modolo LV, Tarsitano CA, Gadelha FR, Hyslop S, et al. Cytotoxicity of goniothalamin enantiomers in renal cancer cells: involvement of nitric oxide, apoptosis and autophagy. Chem Biol Interact. 2008;176(2–3):143–50. doi:10.1016/j.cbi.2008.08.003.CrossRefPubMed de Fátima A, Zambuzzi WF, Modolo LV, Tarsitano CA, Gadelha FR, Hyslop S, et al. Cytotoxicity of goniothalamin enantiomers in renal cancer cells: involvement of nitric oxide, apoptosis and autophagy. Chem Biol Interact. 2008;176(2–3):143–50. doi:10.​1016/​j.​cbi.​2008.​08.​003.CrossRefPubMed
32.
34.
go back to reference Pelizzaro-Rocha KJ, de Jesus MB, Ruela-de-Sousa RR, Nakamura CV, Reis FS, de Fátima A, et al. Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy. Biochim Biophys Acta. 2013;1833(12):2856–65. doi:10.1016/j.bbamcr.2013.07.010.CrossRefPubMed Pelizzaro-Rocha KJ, de Jesus MB, Ruela-de-Sousa RR, Nakamura CV, Reis FS, de Fátima A, et al. Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy. Biochim Biophys Acta. 2013;1833(12):2856–65. doi:10.​1016/​j.​bbamcr.​2013.​07.​010.CrossRefPubMed
35.
go back to reference Barcelos RC, Pelizzaro-Rocha KJ, Pastre JC, Dias MP, Ferreira-Halder CV, Pilli RA. A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness. Eur J Med Chem. 2014;87:745–58. doi:10.1016/j.ejmech.2014.09.085.CrossRefPubMed Barcelos RC, Pelizzaro-Rocha KJ, Pastre JC, Dias MP, Ferreira-Halder CV, Pilli RA. A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness. Eur J Med Chem. 2014;87:745–58. doi:10.​1016/​j.​ejmech.​2014.​09.​085.CrossRefPubMed
36.
go back to reference Kodach LL, Bos CL, Durán N, Peppelenbosch MP, Ferreira CV, Hardwick JC. Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis. 2006;27(3):508–16. doi:10.1093/carcin/bgi307.CrossRefPubMed Kodach LL, Bos CL, Durán N, Peppelenbosch MP, Ferreira CV, Hardwick JC. Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis. 2006;27(3):508–16. doi:10.​1093/​carcin/​bgi307.CrossRefPubMed
44.
go back to reference Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene. 2013;32(29):3420–31. doi:10.1038/onc.2012.355.CrossRefPubMed Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene. 2013;32(29):3420–31. doi:10.​1038/​onc.​2012.​355.CrossRefPubMed
Metadata
Title
Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process
Authors
Paola R. Gonçalves
Karin J. P. Rocha-Brito
Maruska R. N. Fernandes
Julia L. Abrantes
Nelson Durán
Carmen V. Ferreira-Halder
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5265-x

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine